BASIS OF PRESENTATION AND ACCOUNTING POLICIES (Tables)

9 Months Ended

Sep. 30, 2013

BASIS OF PRESENTATION AND ACCOUNTING POLICIES

Concentration of risk

	Percentage of Total Accounts Receivable Balance as of
	September 30, 2013		December 31, 2012
AmerisourceBergen Drug Corporation	20	%	22	%
Cardinal Health, Inc.	17	%	18	%
McKesson Corporation	20	%	20	%

	Percentage of Total Net Revenues for the Three Months Ended  September 30,				Percentage of Total Net Revenues for the Nine Months Ended  September 30,
	2013		2012		2013		2012
AmerisourceBergen Drug Corporation	18	%	20	%	19	%	20	%
Cardinal Health, Inc.	17	%	18	%	17	%	19	%
McKesson Corporation	18	%	18	%	18	%	18	%

Schedule of gross U.S. product revenues offset by provisions

	Three Months Ended  September 30,						Nine Months Ended  September 30,
	2013			2012			2013			2012
	(in thousands)
Gross U.S. product revenues	$	277,999		$	250,881		$	796,217		$	716,906
Provisions offsetting U.S. product revenues:
Contractual adjustments	(13,249		)	(13,535		)	(43,281		)	(40,516		)
Governmental rebates	(21,154		)	(18,992		)	(56,589		)	(54,001		)
Total provisions offsetting product revenues	(34,403		)	(32,527		)	(99,870		)	(94,517		)
U.S. product revenues, net	$	243,596		$	218,354		$	696,347		$	622,389

Summary of basic and diluted net (loss) income per common share

	Three Months Ended  September 30,					Nine Months Ended  September 30,
	2013			2012		2013			2012
	(in thousands, except share and per share amounts)
Net (loss) income, basic	$	(33,895	)	$	40,321	$	(12,565	)	$	116,238
Effect of dilutive securities:
Interest on 2017 Notes, net of tax	—			1,853		—			5,469
Debt issuance costs related to 2017 Notes, net of tax	—			245		—			723
Debt discount amortization related to 2017 Notes, net of tax	—			2,296		—			6,659
Interest on 2013 Notes, net of tax	—			128		—			—
Debt issuance costs related to 2013 Notes, net of tax	—			17		—			—
Debt discount amortization related to 2013 Notes, net of tax	—			316		—			—
Net (loss) income, diluted	$	(33,895	)	$	45,176	$	(12,565	)	$	129,089
Shares used in calculating basic net (loss) income per common share	67,841,665			64,048,673		66,122,521			63,521,491
Effect of dilutive securities:
Options to purchase shares of common stock and RSUs	—			2,262,445		—			2,305,428
2017 Notes convertible into shares of common stock	—			15,424,155		—			15,424,155
2013 Notes convertible into shares of common stock	—			1,121,639		—			—
Shares used in calculating diluted net (loss) income per common share	67,841,665			82,856,912		66,122,521			81,251,074
Net (loss) income per share, basic	$	(0.50	)	$	0.63	$	(0.19	)	$	1.83
Net (loss) income per share, diluted	$	(0.50	)	$	0.55	$	(0.19	)	$	1.59

Potential common shares excluded from calculation of diluted net (loss) income per share, as their inclusion would have been antidilutive

	Three Months Ended  September 30,		Nine Months Ended  September 30,
	2013	2012	2013	2012
Options to purchase shares of common stock and RSUs	8,739,777	2,059,361	8,739,777	2,535,235
Warrants	9,705,442	—	9,705,442	—
2020 Notes convertible into shares of common stock	5,459,311	—	5,459,311	—
2018 Notes convertible into shares of common stock	4,246,131	—	4,246,131	—
2017 Notes convertible into shares of common stock	7,842,943	—	7,842,943	—
2013 Notes convertible into shares of common stock	—	—	—	2,521,856